pocketful Page

Home

Calculator

Calculators

search

Search

whatsapp

Whatsapp

Twenty First Century Management Services Ltd

Venus Remedies Ltd

BSE : 526953|NSE : VENUSREM|ISIN : INE411B01019

Venus Remedies Ltd Company History

Venus Remedies is one of the handful player in pharmaceutical sector to launch injectables globally. It has world-class manufacturing facilities in Panchkula and Baddi (in India), and research and development centre under the name of Venus Medicine Research Centre (in India).

2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2019
2021
2022
2023

2005

Venus Remedies successfully launches its Brand "Ronem"

Venus Remedies announces Strategic Marketing tie up with M/S Cadila Pharmaceuticals Ltd

M/s Themis Medicare Ltd enters into a Strategic Marketing Tie Up with Venus Remedies Ltd.

Delist equity shares from Delhi, Jaipur & Ahmedabad Stock Exchanges.

Venus Remedies has entered into Strategic Marketing Agreement with Merck Specialties Pvt Ltd, a wholly owned Subsidiary of Merck Ltd, Darmstadt, Germany, for its Oncology range of products.

Venus Remedies sets up a wholly owned subsidiary in Germany

2005

history-arrow-left

2006

Venus Remedies Ltd has informed that a Company has been granted three prestigious ISO certifications

Venus Remedies in-licenses product Technology from USA

2006

history-arrow-left

2007

Venus Remedies Ltd has signed an agreement with M/s. Pharma Match R&D B.V. a limited Company based at Amsterdam, Netherlands for jointly preparing, registering and marketing an EU E-CTD Dossier for a latest generation Carbapenem Injectible.

2007

history-arrow-left

2008

Venus facilities Accredited with European GMP Certification.

Venus Remedies Ltd has informed that the Company's manufacturing facilities have been approved by the G.F.T.O of Syria for manufacturing and exporting its products to Syria.

Venus Remedies - European AMP Accreditation for Venus Oncology Facilities.

Venus Remedies Ltd has informed that the Company has successfully launched its fourth Research Product, a Fixed Dose Combination of Cephalosporin with aminoglycoside under the

Brand name "TOBRACEF" in Domestic Market for the first time globally.

2008

history-arrow-left

2009

Venus Remedies - Product Patent for "TOBRACEF" granted in South Africa.

Venus Bags Another Product Patent from South Africa for POTENTOX.

Registered Office of the Company has been shifted from SCO 39, Sector 26, Chandigarh. to SCO 857, C. No. 10, IInd Floor, NAC Manimajra, Chandigarh - 160 101.

2009

history-arrow-left

2010

Venus Remedies Ltd, a fast-growing pharmaceutical company in the country, has launched MEBATIC, a unique antibiotic combination in infusion form to cure severe gastro intestinal (GI) infections.

"Venus Remedies receives GMP Certification from Botswana".

Venus Remedies ties up with IMTECH and Panjab Univ to develop Typhoid detection kits.

The Company has received approval from the Reserve Bank of India for rollover of FCCB USD 5mn, with YTM @4% with maturity till February 15, 2015.

Venus Remedies research Blockbuster "Sulbactomax" gets European Union Patent".

2010

history-arrow-left

2011

"Venus Remedies Anti-Cancer drug "GEMCITABINE" gets UK MHRA approval".

"Sulbactomax" patent from Mexico strengthens Venus Remedies' presence in Latin America".

"Venus Remedies successfully completes Phase I & II Clinical Trials of TUMATREK (VRP162O), cancer detection molecule".

Venus Remedies Ltd wins Gold Medal for TROIS under DST - Lockheed Martin India Innovation Growth Program 2011.

"Venus launches its patented research product ACHNIL” in India".

"Venus Remedies wins "India Manufacturing Excellence Award 2011".

2011

history-arrow-left

2012

VenusRemedis - Venus's ACHNIL, BioSpectrum Product of the Year 2012.

VenusRemedis - Innovative Solution for alleviating cancer.

"Venus Remedies introduces "Ready-to-Use" Single Vial Taxedol in India".

Venus Remedies Limited introduced TROIS that is a research based, patent protected topical nano-emulsion product in India

The Company has won Manufacturing Award for its world class manufacturing and operational excellence at the "Industry 2.0 Manufacturing Innovation Conclave 2012".

"Venus wins Patent award in Silver Category".

2012

history-arrow-left

2013

"Venus Remedies launches Elores - CSE 1034, a US Patent projected product in India".

"Venus Remedies signs MoU for Elores with South African pharmaceutical firm".

"Venus Remedies takes its flagship product, Elores into Latin America".

"Venus launches its first OTC product Ezenus".

"Venus sign Exclusive Marketing Rights deal for its novel Antibiotic Ajuvant Entity to South Africas second largest Pharmaceutical Company - Adcock".

"Venus Remedies MEROPENEM receives market authorization in Mexico".

Venus Remedies Ltd has informed regarding "ELORES awarded Gold Medal for being the best Innovation of 2013"

"Venus wins Innovative 100 Award for ELORES".

"Venus bags UBM India Pharma Award for Elores".

2013

history-arrow-left

2014

"Venus ties up with Mylan for marketing meropenem in three European countries".

"VMRC Drug VRP008 to Fight "MULTI-DRUG Resistant Bacteria" Receives European Patent".

"Venus Receives Market Authorization for Meropenem from SWITZERLAND (SWISSMEDIC)".

2014

history-arrow-left

2015

"Venus announces issuance of Indian Patent for Vancoplus".

Venus Remedies holds blood, organ donation camps on its Panchkula premises.

2015

history-arrow-left

2016

"Venus launches its second OTC product "SWATCH GAURD" a herbal Hand Sanitizer".

2016

history-arrow-left

2019

"Venus announces deal with Cipla for its patented product Elores for Indian Territory".

2019

history-arrow-left

2021

Venus Remedies launched its full-fledged Consumer Healthcare Division.

Venus Remedies Limited has been selected for Production Linked Incentive Scheme (PLI) of the Government of India.

2021

history-arrow-left

2022

Venus Remedies won WHO Good Distribution Practices (GDP) certification for quality services across entire supply chain.

Venus remedies wins ambitionbox best places to work award.

Venus Remedies Limited has been Great Place to Work Certified.

2022

history-arrow-left

2023

"Venus Earns Prestigious FICCI Healthcare Award 2023 for Pioneering ''Organ-on-a-Chip'' Research Model".

"Venus Remedies Limited Honored with Best Working Conditions Award 2022".

Venus Remedies launched flagship R&D drug Elores in Oman.

Venus Remedies  oncology wing product registrations go up to 506 with marketing approvals from four more countries.

"Venus Remedies Awarded Ukrainian GMP Approval for Its Carbapenem, Oncology Parenteral Facilities".

''Venus Remedies awarded Saudi GMP approval for all its production facilities in Baddi.''.

2023

history-arrow-left
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548):

The SEBI Registration No. allotted to us is INZ000313732.
NSE Member Code: 90326| BSE Member Code: 6808| MCX Member Code: 57120
DP CDSL: 12099800

Compliance Officer : Mr. Randhir Kumar Chaudhari
Tel no: 011- 49022222 / 011-49022277
Email: randhir@pocketful.in

Address/Correspondence Address: C- 3, Ground Floor, Okhla Industrial Area, Phase - 1, New Delhi - 110020

For any complaints, drop us an email at legal@pocketful.in

Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID.

Smart Online Dispute Resolution|Link To Circular|Procedures and Policies|Broker Investor Charter|DP Investor Charter

Benefits: Effective Communication, Speedy redressal of the grievances.

Please ensure you carefully read the Risk Disclosure Document as prescribed by SEBI and our Terms of Use and Privacy Policy.
The brand name Pocketful and logo is in process of trademarks registration. The cost-effective brokerage plans make Pocketful a trustworthy and reliable online stock broker. Available on both the web and mobile, it offers unmatched convenience to traders. If you are considering opening......

Read More